Brainsway Ltd. Stock Price, News & Analysis

BrainsWay Ltd. (NASDAQ: BWAY) reported a 34% revenue growth in 2021, reaching $29.7 million, compared to $22.1 million in 2020. Fourth-quarter revenues rose 20% to $8.5 million. The company improved its cash position to $57.3 million, reflecting positive operational cash flow. Notably, BrainsWay received a Local Coverage Determination from Medicare, expanding coverage for Deep TMS therapy to 60 million patients. Gross margins remained steady at 77%, while operating expenses increased to $8.0 million. The net loss for the year was $6.5 million.

Burlington, Mass., and Jerusalem, March 01, 2022 - BrainsWay Ltd. (NASDAQ: BWAY) announced that CEO Christopher von Jako, Ph.D., will present at the 32nd Annual Oppenheimer Healthcare Conference. The event will take place from March 15 to March 17, 2022, with BrainsWay's presentation scheduled for March 16 at 2:40 PM ET. The company specializes in noninvasive neurostimulation treatments for mental health disorders, including major depressive disorder and obsessive-compulsive disorder. Investors interested in meetings should contact their Oppenheimer representative.

BURLINGTON, Mass. and JERUSALEM, Feb. 28, 2022 – BrainsWay Ltd. (NASDAQ: BWAY) will report its fourth quarter and full year 2021 financial results on March 9, 2022, before U.S. markets open. A conference call and webcast, scheduled for 8:30 AM ET, will discuss the results and operational updates. BrainsWay is a leader in noninvasive neurostimulation for mental health, with FDA-cleared treatments for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The company aims to raise awareness and access to its Deep TMS technology, supported by robust clinical evidence.

BrainsWay Ltd. (NASDAQ: BWAY) announced new research validating its Deep TMS™ treatment for anxiety symptoms associated with depression. The analysis, published in the Journal of Clinical Medicine, analyzed data from multiple trials, revealing that Deep TMS is significantly effective for patients with high anxiety, a group traditionally seen as less responsive to treatment. These findings enhance BrainsWay's leadership in psychiatric care, providing potential hope for the many patients experiencing anxious depression, which affects an estimated 13 to 19 million adults in the U.S. annually.

BURLINGTON, Mass. and JERUSALEM, Feb. 01, 2022 – BrainsWay (NASDAQ: BWAY), a leader in noninvasive neurostimulation for mental health disorders, announced its CEO, Christopher von Jako, will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 15-17, 2022. A fireside chat is scheduled for February 15 at 9:30am ET. The company aims to enhance awareness and access to its Deep TMS technology, which treats conditions like major depressive disorder and smoking addiction. Investors interested in meetings should contact their BTIG representative.

BrainsWay Ltd. (NASDAQ: BWAY) announced that the Medicare Administrative Contractor, Palmetto GBA, will cover the Deep TMS™ system for treating Obsessive-Compulsive Disorder (OCD) in seven states, effective March 13, 2022. This coverage expands access to over 9 million additional Medicare patients, bringing the total to approximately 60 million covered lives. The decision underscores the clinical efficacy of Deep TMS for OCD treatment, aligning with the Clinical TMS Society's recommendations.

BrainsWay Ltd. (NASDAQ: BWAY) has appointed Professor Markus Heilig, an expert in addiction and anxiety treatment, to its scientific advisory board. Professor Heilig, who has a notable background in neuroscience and previously directed clinical research at the National Institute on Alcohol Abuse and Alcoholism, will guide BrainsWay's research strategies, particularly in Deep TMS™ therapy. This appointment underscores BrainsWay's commitment to advancing neuroscience amid urgent mental health needs and aims to enhance treatment efficacy for mental health disorders.

BrainsWay Ltd. (NASDAQ: BWAY) announced promising research data validating the durability and cost-effectiveness of Deep TMS for treating Obsessive-Compulsive Disorder (OCD). Key findings from studies published in peer-reviewed journals indicate that 86.7% of patients experienced treatment durability of over one year, with significant reductions in functional disability. Additionally, Deep TMS was shown to be a cost-effective alternative compared to other treatment methods, addressing a significant healthcare burden exceeding $7 billion annually in the U.S.

BrainsWay Ltd. has published findings from a randomized, placebo-controlled pilot study on its Deep TMS™ System aimed at reducing alcohol consumption and cravings in adults with Alcohol Use Disorder (AUD). Conducted with 46 subjects, results showed a significant decrease in heavy drinking days—2.9 for the treatment group compared to 10.6 for placebo. The study highlights the potential of Deep TMS in addressing AUD, particularly amidst rising cases exacerbated by the pandemic. No serious adverse events were reported, marking a promising step for future treatments in this area.